Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: The Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Chang, Po Yuan ^a   Lee, Chii Ming ^a   Hsu, Hsiu Ching ^a   Lin, Hung Ju ^a   Chien, Kuo Liong ^a   Chen, Ming Fong ^a   Chen, Chu Huang ^b,c,d,e   Lee, Yuan Teh ^a,d   Yang, Chao Yuh ^b,c,d,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS HEART INSTITUTE   (United States)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apolipoprotein CIII (ApoCIII); Apolipoproteins; Cardiovascular risk factors; Chin Shan Community Cardiovascular Cohort (CCCC) Study; Coronary artery disease; High density lipoprotein (HDL); Lipoproteins; Very low density lipoprotein (VLDL)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; TAIWAN;

AGED; APOLIPOPROTEIN C-III; BIOLOGICAL MARKERS; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; PROGNOSIS; TAIWAN; TRIGLYCERIDES;

EID: 84869865053     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-162     Document Type: Article

References (30)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 25 3143 3421 12485966
2. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. Arsenault BJ, Rana JS, Stroes ES, Despres JP, Shah PK, Kastelein JJ, Wareham NJ, Boekholdt SM, Khaw KT, J Am Coll Cardiol 2009 55 1 35 41 10.1016/j.jacc.2009.07.057 20117361
3. Major lipids, apolipoproteins, and risk of vascular disease. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, et al. JAMA 2009 302 18 1993 2000 19903920
4. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Parish S, Peto R, Palmer A, Clarke R, Lewington S, Offer A, Whitlock G, Clark S, Youngman L, Sleight P, et al. Eur Heart J 2009 30 17 2137 2146 10.1093/eurheartj/ehp221 19520708
5. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E, Lancet 2001 358 9298 2026 2033 10.1016/S0140-6736(01)07098-2 11755609 (Pubitemid 34084825)
6. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM, Circulation 2006 113 5 691 700 10.1161/CIRCULATIONAHA.105.591743 16461842
7. Apolipoprotein CIII links dyslipidemia with atherosclerosis. Kawakami A, Yoshida M, J Atheroscler Thromb 2009 16 1 6 11 10.5551/jat.E607 19262004
8. Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men. Shin MJ, Krauss RM, Atherosclerosis 2010 211 1 337 341 10.1016/j. atherosclerosis.2010.02.025 20303494
9. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL, Science 1990 249 4970 790 793 10.1126/science.2167514 2167514
10. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. Qu S, Perdomo G, Su D, D'Souza FM, Shachter NS, Dong HH, J Lipid Res 2007 48 7 1476 1487 10.1194/jlr.M600498-JLR200 17438339 (Pubitemid 47312010)
11. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Marcoux C, Tremblay M, Fredenrich A, Davignon J, Cohn JS, Metabolism: clinical and experimental 2001 50 1 112 119 10.1053/meta.2001.19452 (Pubitemid 32058558)
12. Very low density lipoprotein. Fate of phospholipids, cholesterol, and apolipoprotein C during lipolysis in vitro. Eisenberg S, Olivecrona T, Lipid Res 1979 20 5 614 623 (Pubitemid 9230554)
13. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. Sehayek E, Eisenberg S, J Biol Chem 1991 266 27 18259 18267 1917954 (Pubitemid 21908074)
14. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. Le NA, Gibson JC, Ginsberg HN, J Lipid Res 1988 29 5 669 677 3411241
15. Chin-Shan Community Cardiovascular Cohort in Taiwan-baseline data and five-year follow-up morbidity and mortality. Lee Y, Lin RS, Sung FC, Yang C, Chien K, Chen W, Su T, Hsu H, Huang Y, J Clin Epidemiol 2000 53 8 838 846 10.1016/S0895-4356(00)00198-0 10942867 (Pubitemid 30609649)
16. Left ventricular mass and risk of cardiovascular events and all-cause death among ethnic Chinese-the Chin-Shan Community Cardiovascular Cohort study. Lai CL, Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Int J Cardiol 2011 149 3 347 352 10.1016/j.ijcard.2010.02.015 20202708
17. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man. Redgrave TG, Carlson LA, J Lipid Res 1979 20 2 217 229 220359 (Pubitemid 9150669)
18. ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: ApoE in ApoB-containing lipoproteins (Lp B:E) and ApoB in ApoE-containing lipoproteins (Lp E:B). Yang CY, Xie YH, Yang M, Quion JA, Gotto AM Jr, J Protein Chem 1995 14 7 503 509 10.1007/BF01886876 8561846
19. Human intestinal lipoproteins. Green PH, Glickman RM, Saudek CD, Blum CB, Tall AR, Studies in chyluric subjects. J Clin Invest 1979 64 1 233 242
20. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E, Circulation 2000 102 16 1886 1892 10.1161/01.CIR.102.16.1886 11034934
21. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Lee SJ, Campos H, Moye LA, Sacks FM, Arterioscler Thromb Vasc Biol 2003 23 5 853 858 10.1161/01.ATV.0000066131.01313. EB 12637336 (Pubitemid 36566177)
22. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content. Khoo C, Campos H, Judge H, Sacks FM, J Lipid Res 1999 40 2 202 212 9925648 (Pubitemid 29069793)
23. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. Ebara T, Ramakrishnan R, Steiner G, Shachter NS, J Clin Invest 1997 99 11 2672 2681 10.1172/JCI119456 9169497 (Pubitemid 27259814)
24. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde. Luc G, Fievet C, Arveiler D, Evans AE, Bard JM, Cambien F, Fruchart JC, Ducimetiere P, J Lipid Res 1996 37 3 508 517 8728314 (Pubitemid 26134357)
25. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. Jong MC, Rensen PC, Dahlmans VE, van der Boom H, van Berkel TJ, Havekes LM, J Lipid Res 2001 42 10 1578 1585 11590213 (Pubitemid 33026056)
26. Atherogenicity of triglyceride-rich lipoproteins. Krauss RM, Am J Cardiol 1998 81 4A 13B 17B 9526808 (Pubitemid 28113940)
27. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT, Atherosclerosis 2005 183 1 147 155 10.1016/j. atherosclerosis.2005.01.018 16154134 (Pubitemid 41416833)
28. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E, Clin Chem 1998 44 8 Pt 1 1641 1649 9702950 (Pubitemid 28381205)
29. The role of dysfunctional HDL in atherosclerosis. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM, J Lipid Res 2009 50 Suppl 145 S149 18955731
30. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, et al. J Clin Invest 2004 114 4 529 541 15314690 (Pubitemid 39572103)